Gynecological malignancies in elderly patients: Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study

Marcello Ceccaroni, Giuseppe D'Agostino, Gabriella Ferrandina, Angiolo Gadducci, Giovanni Di Vagno, Sandro Pignata, Antonella Poerio, Maria Giovanna Salerno, Antonio Fanucchi, Maria Teresa Lapresa, Rosa Tambaro, Giovanni Scambia

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. One hundred and forty-eight consecutive gynecological oncological patients aged ≥70 were administered chemotherapy during the years 1990-2000. Methods. Median age was 73 years (range 70-84). Fifty-five (37.2%) women were over 75 years old. One or more comorbid conditions were present in 118 (79.7%) patients. Standard schedules were administered to 97.3% of cases, with a total number of 1046 cycles of therapy administered (median, 6; range, 1-35, per patient). Results. Of a total of 233 chemotherapy regimens globally administered, G3-G4 hematological toxicity was documented in 38.2% of cases. Only 10 (6.8%) of the 148 patients discontinued treatment because of G3-G4 hematological toxicity. No severe nonhematological toxicity was observed. Two dose reductions and three treatment delays, but no discontinuation of treatment, were required during second-line regimens. Treatment delay >7 days was required in 16.9% of cases. Conclusions. Chronological age did not adversely influence the ability to receive aggressive treatment.

Original languageEnglish
Pages (from-to)445-450
Number of pages6
JournalGynecologic Oncology
Volume85
Issue number3
DOIs
Publication statusPublished - 2002

Keywords

  • Age
  • Chemotherapy
  • Comorbidity
  • Discontinuation
  • Dose reduction
  • Elderly
  • Oncological
  • Performance status
  • Toxicity

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Gynecological malignancies in elderly patients: Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study'. Together they form a unique fingerprint.

Cite this